Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors

Jianhui Ma, Wen Liu, Jiali Li, Daehwan Kim, Sangyub Kim, Alexandra Levy, Zhen Cai, Kevin D. Bunker, Alejandro Recio-Boiles, Jennifer M. Segar, Shiraj Sen, Deborah B. Doroshow, Danielle Jandial, Michael Rutgard, Olivier Harismendy, Stephan K. Grant, Ahmed A. Samatar, Kimberlee M. Fischer, Mark R. Lackner

Mol Cancer Ther OF1–OF15.

https://doi.org/10.1158/1535-7163.MCT-24-1194

Published: 05 May 2025

View articletitled, Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors

Includes: Supplementary data

Journal Articles

Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models

Heather M. Moore, Heidi M. Savage, Carol O'Brien, Wei Zhou, Ethan S. Sokol, Michael E. Goldberg, Ciara Metcalfe, Lori S. Friedman, Mark R. Lackner, Timothy R. Wilson

Mol Cancer Ther (2020) 19 (1): 292–303.

https://doi.org/10.1158/1535-7163.MCT-19-0284

Published: 03 January 2020

View articletitled, Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models

Includes: Supplementary data

Journal Articles

Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer

Jill M. Spoerke, Vicky Makker, Carol Aghajanian, Powles Thomas, Robert J. Motzer, Jennifer O. Lauchle, Hema Parmar, Houston Gilbert, Wei Lin, Bridget O'Keeffe, Michelle Byrtek, Hartmut Koeppen, Yulei Wang, Shan Lu, Ling-Yuh Huw, Garret M. Hampton, Mark R. Lackner

Mol Cancer Ther (2015) 14 (7_Supplement): A03.

https://doi.org/10.1158/1538-8514.PI3K14-A03

Published: 06 July 2015

View articletitled, Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer

Journal Articles

Abstract B03: Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors

Yoshito Nakanishi, Jill M. Spoerke, Mika Derynck, Jennifer O. Lauchle, Hartmut Koeppen, Jill Fredrickson, Joseph Ware, Garret Hampton, Yibing Yan, Mark R. Lackner

Mol Cancer Ther (2015) 14 (7_Supplement): B03.

https://doi.org/10.1158/1538-8514.PI3K14-B03

Published: 06 July 2015

View articletitled, Abstract B03: Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors

Journal Articles

HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

Elicia Penuel, Congfen Li, Vaishali Parab, Luciana Burton, Kyra J. Cowan, Mark Merchant, Robert L. Yauch, Premal Patel, Amy Peterson, Garret M. Hampton, Mark R. Lackner, Priti S. Hegde

Mol Cancer Ther (2013) 12 (6): 1122–1130.

https://doi.org/10.1158/1535-7163.MCT-13-0015

Published: 09 June 2013

View articletitled, HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

Mol Cancer Ther (2012) 11 (5): 1143–1154.

https://doi.org/10.1158/1535-7163.MCT-11-1010

Published: 08 May 2012

View articletitled, ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

Includes: Supplementary data

Journal Articles

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Mol Cancer Ther (2011) 10 (12): 2426–2436.

https://doi.org/10.1158/1535-7163.MCT-11-0446

Published: 07 December 2011

View articletitled, GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Includes: Supplementary data

Journal Articles

Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

Jiping Zha, Carol O'Brien, Heidi Savage, Ling-Yuh Huw, Fiona Zhong, Leanne Berry, Gail D. Lewis Phillips, Elizabeth Luis, Guy Cavet, Xiaolan Hu, Lukas C. Amler, Mark R. Lackner

Mol Cancer Ther (2009) 8 (8): 2110–2121.

https://doi.org/10.1158/1535-7163.MCT-09-0381

Published: 14 August 2009

View articletitled, Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

Includes: Supplementary data

Journal Articles

Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays

Zachary S. Boyd, Qun Jenny Wu, Carol O'Brien, Jill Spoerke, Heidi Savage, Paul J. Fielder, Lukas Amler, Yibing Yan, Mark R. Lackner

Mol Cancer Ther (2008) 7 (12): 3695–3706.

https://doi.org/10.1158/1535-7163.MCT-08-0810

Published: 15 December 2008

View articletitled, Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays

Includes: Supplementary data

Journal Articles

Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake

Mol Cancer Ther (2008) 7 (9): 2599–2608.

https://doi.org/10.1158/1535-7163.MCT-07-2401

Published: 11 September 2008

View articletitled, Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors

Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models

Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer

Abstract B03: Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors

HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays

Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only